Staff Members - Benha University
The Significance of Aldehyde Dehydrogenase 1A1 Expression in Benign Prostatic Hyperplasia, Prostatic Intraepithelial Neoplasia and Prostatic Adenocarcinoma
• 2020
Publication Information
Authors
Sara G. Masoud, Magda H. Bakr, Nashwa M. Emara, Sarah N. Nasif
Keywords
ALDH1A1, BPH, HGPIN, prostatic adenocarcinoma.
Journal
Not Available
Publisher
Not Available
Volume
Not Available
Issue
Not Available
Pages
Not Available
publication.type
Local
Paper Link
Not Available
Supplementary Materials
Not Available
Abstract
Background: Prostatic carcinoma contains a small population of
cancer stem cells (CSCs) that promote tumor growth, maintenance,
and progression. CSC markers could provide a prognostic tool for
human malignancies. Therefore, CSCs may have a role in prostatic
carcinoma. This study aimed to evaluate the expression patterns and
significance of stem cell marker aldehyde dehydrogenase 1A1
(ALDH1A1) in prostatic adenocarcinoma. Methods: This is a
retrospective study performed upon 60 cases grouped as; 10 cases
(16.7%) of benign prostatic hyperplasia (BPH), 6 cases (10%) of highgrade prostatic intraepithelial neoplasia (HGPIN) and 44 cases
(73.3%) of prostatic adenocarcinoma (PCa) of different Gleason
scores. Immunohistochemistry was applied on formalin-fixed,
paraffin-embedded blocks using ALDH1A1. The relation between
ALDH1A1 expression and clinicopathologic parameters was assessed.
Results: Low expression of ALDH1A1 was seen in all cases (100%)
of BPH, 5/6 (83.3%) of HGPIN and 12/44 (27.3%) of PCa, while high
expression was in 1/6 case (16.7%) of HGPIN and 32/44 (72.2%) of
PCa cases. There were significant relations between the expression
levels of ALDH1A1 in PCa compared with HGPIN and BPH cases
(P
cancer stem cells (CSCs) that promote tumor growth, maintenance,
and progression. CSC markers could provide a prognostic tool for
human malignancies. Therefore, CSCs may have a role in prostatic
carcinoma. This study aimed to evaluate the expression patterns and
significance of stem cell marker aldehyde dehydrogenase 1A1
(ALDH1A1) in prostatic adenocarcinoma. Methods: This is a
retrospective study performed upon 60 cases grouped as; 10 cases
(16.7%) of benign prostatic hyperplasia (BPH), 6 cases (10%) of highgrade prostatic intraepithelial neoplasia (HGPIN) and 44 cases
(73.3%) of prostatic adenocarcinoma (PCa) of different Gleason
scores. Immunohistochemistry was applied on formalin-fixed,
paraffin-embedded blocks using ALDH1A1. The relation between
ALDH1A1 expression and clinicopathologic parameters was assessed.
Results: Low expression of ALDH1A1 was seen in all cases (100%)
of BPH, 5/6 (83.3%) of HGPIN and 12/44 (27.3%) of PCa, while high
expression was in 1/6 case (16.7%) of HGPIN and 32/44 (72.2%) of
PCa cases. There were significant relations between the expression
levels of ALDH1A1 in PCa compared with HGPIN and BPH cases
(P